 Connection
Kyle Rove to Prostate-Specific Antigen
This is a "connection" page, showing publications Kyle Rove has written about Prostate-Specific Antigen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.570 |
|
|
|
-
Rove KO, Crawford ED. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol. 2012 Apr; 30(2):137-42.
Score: 0.355
-
Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO. Maximal testosterone suppression in prostate cancer--free vs total testosterone. Urology. 2014 Jun; 83(6):1217-22.
Score: 0.105
-
Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU Int. 2011 Dec; 108(11):1743-9.
Score: 0.086
-
Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL, Bostwick DG. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012 Nov; 188(5):1726-31.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|